Ranitidine drugs in Canada: May contain NDMA above acceptable levels
In plain language
This recall involves over-the-counter and prescription ranitidine drugs sold in Canada. They are being recalled because they may contain N-nitrosodimethylamine (NDMA) above acceptable levels. Do not stop taking prescription ranitidine without first consulting your healthcare provider.
What to do
- Do not stop taking your prescription ranitidine drug unless you have spoken to your healthcare provider.
- Contact your healthcare provider if you have concerns about your health or questions about alternative treatment options.
- Report any health product adverse events or complaints to Health Canada.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Specific affected products are listed in the official notice.
Why this matters
May contain NDMA above acceptable levels
Do I have this product?
This recall applies to specific products. Details are listed in the official notice.
Frequently Asked Questions
Why was this product recalled?
May contain NDMA above acceptable levels
What should consumers do?
Do not stop taking your prescription ranitidine drug unless you have spoken to your healthcare provider. Contact your healthcare provider if you have concerns about your health or questions about alternative treatment options. Report any health product adverse events or complaints to Health Canada.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. May contain NDMA above acceptable levels
When was this product recalled?
This product was recalled on July 23, 2020.